Clinical trial · Interventional
Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma
A Phase II Placebo-controlled Intervention Trial of Oral Aspirin (ASA) as a UV Protectant in Vivo
NCT04066725CI-TRIAL-00056621completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a phase II placebo-controlled intervention trial assessing aspirin (ASA) as a UV protectant in patients at risk for melanoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Melanoma (Skin) | Melanoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (3)
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- ASA 81 mg daily
- description
- Participants will be given ASA 81 mg orally once daily for a total of 60 days
- interventionNames
- Drug: Aspirin 81 mg
- type
- EXPERIMENTAL
- label
- ASA 325 mg daily
- description
- Participants will be given ASA 325 mg orally once daily for a total of 60 days.
- interventionNames
- Drug: Aspirin 325mg
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- Participants will be given a placebo orally once daily for a total of 60 days.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Must have at least 2 nevi (each \>5 mm diameter) not clinically suspicious for melanoma that can be biopsied. * Must be older than age 18. * Must be able to receive informed consent and sign an approved consent form that conforms to federal and institutional guidelines. Exclusion Criteria: * The patient cannot speak / understand English or Spanish. * The patient is pregnant or breastfeeding. * The patient is a prisoner, critically or mentally ill, or otherwise incapacitated or considered vulnerable. * The patient has history of allergic reaction to ASA. * The patient has history of severe asthma. * The patient has been taking ASA or any NSAID in the past 2 weeks. * The patient has been taking a blood thinner in the past 2 weeks. * The patient has history of bleeding disorder. * The patient has history of peptic ulcer disease. * The patient has had recent intense UV exposure in the past month.
References
Publications (0)
Data not yet available
No reference posted for this study.